Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid.
Identifieur interne : 000E72 ( PubMed/Checkpoint ); précédent : 000E71; suivant : 000E73Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid.
Auteurs : Buranee Kanchanatawan [Thaïlande] ; Sunee Sirivichayakul [Thaïlande] ; Kiat Ruxrungtham [Thaïlande] ; André F. Carvalho [Brésil] ; Michel Geffard [France] ; Heidi Ormstad [Norvège] ; George Anderson [Royaume-Uni] ; Michael Maes [Thaïlande]Source :
- Molecular neurobiology [ 1559-1182 ] ; 2017.
Abstract
Evidence suggests that activation of the tryptophan catabolite (TRYCAT) pathway is involved in the pathophysiology of schizophrenia. However, no previous study examined whether TRYCAT pathway activation is associated with deficit schizophrenia. We measured IgA responses to TRYCATs, namely quinolinic acid, picolinic acid, kynurenic acid, xanthurenic acid, and anthranilic acid and 3-OH-kynurenine, in 40 healthy controls and in schizophrenic patients with (n = 40) and without (n = 40) deficit, defined according to the Schedule for the Deficit Syndrome (SDS). Primary deficit schizophrenia is accompanied by an activated TRYCAT pathway as compared to controls and nondeficit schizophrenia. Participants with deficit schizophrenia show increased IgA responses to xanthurenic acid, picolinic acid, and quinolinic acid and relatively lowered IgA responses to kynurenic and anthranilic acids, as compared to patients with nondeficit schizophrenia. Both schizophrenia subgroups show increased IgA responses to 3-OH-kynurenine as compared to controls. The IgA responses to noxious TRYCATs, namely xanthurenic acid, picolinic acid, quinolinic acid, and 3-OH-kynurenine, but not protective TRYCATS, namely anthranilic acid and kunyrenic acid, are significantly higher in deficit schizophrenia than in controls. The negative symptoms of schizophrenia are significantly and positively associated with increased IgA responses directed against picolinic acid and inversely with anthranilic acid, whereas no significant associations between positive symptoms and IgA responses to TRYCATs were found. In conclusion, primary deficit schizophrenia is characterized by TRYCAT pathway activation and differs from nondeficit schizophrenia by a highly specific TRYCAT pattern suggesting increased excitotoxicity, cytotoxicity, and neurotoxicity, as well as inflammation and oxidative stress. The specific alterations in IgA responses to TRYCATs provide further insight for the biological delineation of deficit versus nondeficit schizophrenia.
DOI: 10.1007/s12035-017-0417-6
PubMed: 28181189
Affiliations:
- Brésil, France, Norvège, Royaume-Uni, Thaïlande
- Angleterre, Aquitaine, Aquitaine-Limousin-Poitou-Charentes, Ceará, Grand Londres
- Bordeaux, Londres, Talence
- Université fédérale du Ceará
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:28181189Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid.</title>
<author><name sortKey="Kanchanatawan, Buranee" sort="Kanchanatawan, Buranee" uniqKey="Kanchanatawan B" first="Buranee" last="Kanchanatawan">Buranee Kanchanatawan</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sirivichayakul, Sunee" sort="Sirivichayakul, Sunee" uniqKey="Sirivichayakul S" first="Sunee" last="Sirivichayakul">Sunee Sirivichayakul</name>
<affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Faculty of Medicine, Chulalongkorn University, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ruxrungtham, Kiat" sort="Ruxrungtham, Kiat" uniqKey="Ruxrungtham K" first="Kiat" last="Ruxrungtham">Kiat Ruxrungtham</name>
<affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Faculty of Medicine, Chulalongkorn University, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Carvalho, Andre F" sort="Carvalho, Andre F" uniqKey="Carvalho A" first="André F" last="Carvalho">André F. Carvalho</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Clinical Medicine and Translational Psychiatry Research Group, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Department of Clinical Medicine and Translational Psychiatry Research Group, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE</wicri:regionArea>
<placeName><region type="state">Ceará</region>
</placeName>
<orgName type="university">Université fédérale du Ceará</orgName>
</affiliation>
</author>
<author><name sortKey="Geffard, Michel" sort="Geffard, Michel" uniqKey="Geffard M" first="Michel" last="Geffard">Michel Geffard</name>
<affiliation wicri:level="3"><nlm:affiliation>IDRPHT, Research Department, Talence, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>IDRPHT, Research Department, Talence</wicri:regionArea>
<placeName><region type="region" nuts="2">Aquitaine-Limousin-Poitou-Charentes</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Talence</settlement>
<settlement type="city" wicri:auto="agglo">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ormstad, Heidi" sort="Ormstad, Heidi" uniqKey="Ormstad H" first="Heidi" last="Ormstad">Heidi Ormstad</name>
<affiliation wicri:level="1"><nlm:affiliation>Faculty of Health Sciences, University College of Southeast Norway, Drammen, Norway.</nlm:affiliation>
<country xml:lang="fr">Norvège</country>
<wicri:regionArea>Faculty of Health Sciences, University College of Southeast Norway, Drammen</wicri:regionArea>
<wicri:noRegion>Drammen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Anderson, George" sort="Anderson, George" uniqKey="Anderson G" first="George" last="Anderson">George Anderson</name>
<affiliation wicri:level="3"><nlm:affiliation>CRC Scotland & London, Eccleston Square, London, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>CRC Scotland & London, Eccleston Square, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Maes, Michael" sort="Maes, Michael" uniqKey="Maes M" first="Michael" last="Maes">Michael Maes</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. dr.michaelmaes@hotmail.com.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28181189</idno>
<idno type="pmid">28181189</idno>
<idno type="doi">10.1007/s12035-017-0417-6</idno>
<idno type="wicri:Area/PubMed/Corpus">001140</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001140</idno>
<idno type="wicri:Area/PubMed/Curation">001137</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001137</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001137</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001137</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid.</title>
<author><name sortKey="Kanchanatawan, Buranee" sort="Kanchanatawan, Buranee" uniqKey="Kanchanatawan B" first="Buranee" last="Kanchanatawan">Buranee Kanchanatawan</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sirivichayakul, Sunee" sort="Sirivichayakul, Sunee" uniqKey="Sirivichayakul S" first="Sunee" last="Sirivichayakul">Sunee Sirivichayakul</name>
<affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Faculty of Medicine, Chulalongkorn University, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ruxrungtham, Kiat" sort="Ruxrungtham, Kiat" uniqKey="Ruxrungtham K" first="Kiat" last="Ruxrungtham">Kiat Ruxrungtham</name>
<affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Faculty of Medicine, Chulalongkorn University, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Carvalho, Andre F" sort="Carvalho, Andre F" uniqKey="Carvalho A" first="André F" last="Carvalho">André F. Carvalho</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Clinical Medicine and Translational Psychiatry Research Group, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Department of Clinical Medicine and Translational Psychiatry Research Group, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE</wicri:regionArea>
<placeName><region type="state">Ceará</region>
</placeName>
<orgName type="university">Université fédérale du Ceará</orgName>
</affiliation>
</author>
<author><name sortKey="Geffard, Michel" sort="Geffard, Michel" uniqKey="Geffard M" first="Michel" last="Geffard">Michel Geffard</name>
<affiliation wicri:level="3"><nlm:affiliation>IDRPHT, Research Department, Talence, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>IDRPHT, Research Department, Talence</wicri:regionArea>
<placeName><region type="region" nuts="2">Aquitaine-Limousin-Poitou-Charentes</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Talence</settlement>
<settlement type="city" wicri:auto="agglo">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ormstad, Heidi" sort="Ormstad, Heidi" uniqKey="Ormstad H" first="Heidi" last="Ormstad">Heidi Ormstad</name>
<affiliation wicri:level="1"><nlm:affiliation>Faculty of Health Sciences, University College of Southeast Norway, Drammen, Norway.</nlm:affiliation>
<country xml:lang="fr">Norvège</country>
<wicri:regionArea>Faculty of Health Sciences, University College of Southeast Norway, Drammen</wicri:regionArea>
<wicri:noRegion>Drammen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Anderson, George" sort="Anderson, George" uniqKey="Anderson G" first="George" last="Anderson">George Anderson</name>
<affiliation wicri:level="3"><nlm:affiliation>CRC Scotland & London, Eccleston Square, London, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>CRC Scotland & London, Eccleston Square, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Maes, Michael" sort="Maes, Michael" uniqKey="Maes M" first="Michael" last="Maes">Michael Maes</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. dr.michaelmaes@hotmail.com.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Molecular neurobiology</title>
<idno type="eISSN">1559-1182</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Evidence suggests that activation of the tryptophan catabolite (TRYCAT) pathway is involved in the pathophysiology of schizophrenia. However, no previous study examined whether TRYCAT pathway activation is associated with deficit schizophrenia. We measured IgA responses to TRYCATs, namely quinolinic acid, picolinic acid, kynurenic acid, xanthurenic acid, and anthranilic acid and 3-OH-kynurenine, in 40 healthy controls and in schizophrenic patients with (n = 40) and without (n = 40) deficit, defined according to the Schedule for the Deficit Syndrome (SDS). Primary deficit schizophrenia is accompanied by an activated TRYCAT pathway as compared to controls and nondeficit schizophrenia. Participants with deficit schizophrenia show increased IgA responses to xanthurenic acid, picolinic acid, and quinolinic acid and relatively lowered IgA responses to kynurenic and anthranilic acids, as compared to patients with nondeficit schizophrenia. Both schizophrenia subgroups show increased IgA responses to 3-OH-kynurenine as compared to controls. The IgA responses to noxious TRYCATs, namely xanthurenic acid, picolinic acid, quinolinic acid, and 3-OH-kynurenine, but not protective TRYCATS, namely anthranilic acid and kunyrenic acid, are significantly higher in deficit schizophrenia than in controls. The negative symptoms of schizophrenia are significantly and positively associated with increased IgA responses directed against picolinic acid and inversely with anthranilic acid, whereas no significant associations between positive symptoms and IgA responses to TRYCATs were found. In conclusion, primary deficit schizophrenia is characterized by TRYCAT pathway activation and differs from nondeficit schizophrenia by a highly specific TRYCAT pattern suggesting increased excitotoxicity, cytotoxicity, and neurotoxicity, as well as inflammation and oxidative stress. The specific alterations in IgA responses to TRYCATs provide further insight for the biological delineation of deficit versus nondeficit schizophrenia.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">28181189</PMID>
<DateCreated><Year>2017</Year>
<Month>02</Month>
<Day>09</Day>
</DateCreated>
<DateRevised><Year>2017</Year>
<Month>02</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-1182</ISSN>
<JournalIssue CitedMedium="Internet"><PubDate><Year>2017</Year>
<Month>Feb</Month>
<Day>08</Day>
</PubDate>
</JournalIssue>
<Title>Molecular neurobiology</Title>
<ISOAbbreviation>Mol. Neurobiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid.</ArticleTitle>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s12035-017-0417-6</ELocationID>
<Abstract><AbstractText>Evidence suggests that activation of the tryptophan catabolite (TRYCAT) pathway is involved in the pathophysiology of schizophrenia. However, no previous study examined whether TRYCAT pathway activation is associated with deficit schizophrenia. We measured IgA responses to TRYCATs, namely quinolinic acid, picolinic acid, kynurenic acid, xanthurenic acid, and anthranilic acid and 3-OH-kynurenine, in 40 healthy controls and in schizophrenic patients with (n = 40) and without (n = 40) deficit, defined according to the Schedule for the Deficit Syndrome (SDS). Primary deficit schizophrenia is accompanied by an activated TRYCAT pathway as compared to controls and nondeficit schizophrenia. Participants with deficit schizophrenia show increased IgA responses to xanthurenic acid, picolinic acid, and quinolinic acid and relatively lowered IgA responses to kynurenic and anthranilic acids, as compared to patients with nondeficit schizophrenia. Both schizophrenia subgroups show increased IgA responses to 3-OH-kynurenine as compared to controls. The IgA responses to noxious TRYCATs, namely xanthurenic acid, picolinic acid, quinolinic acid, and 3-OH-kynurenine, but not protective TRYCATS, namely anthranilic acid and kunyrenic acid, are significantly higher in deficit schizophrenia than in controls. The negative symptoms of schizophrenia are significantly and positively associated with increased IgA responses directed against picolinic acid and inversely with anthranilic acid, whereas no significant associations between positive symptoms and IgA responses to TRYCATs were found. In conclusion, primary deficit schizophrenia is characterized by TRYCAT pathway activation and differs from nondeficit schizophrenia by a highly specific TRYCAT pattern suggesting increased excitotoxicity, cytotoxicity, and neurotoxicity, as well as inflammation and oxidative stress. The specific alterations in IgA responses to TRYCATs provide further insight for the biological delineation of deficit versus nondeficit schizophrenia.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kanchanatawan</LastName>
<ForeName>Buranee</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sirivichayakul</LastName>
<ForeName>Sunee</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ruxrungtham</LastName>
<ForeName>Kiat</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Carvalho</LastName>
<ForeName>André F</ForeName>
<Initials>AF</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Medicine and Translational Psychiatry Research Group, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Geffard</LastName>
<ForeName>Michel</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>IDRPHT, Research Department, Talence, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>GEMAC, Saint Jean d'Illac, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ormstad</LastName>
<ForeName>Heidi</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Faculty of Health Sciences, University College of Southeast Norway, Drammen, Norway.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Anderson</LastName>
<ForeName>George</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>CRC Scotland & London, Eccleston Square, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Maes</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. dr.michaelmaes@hotmail.com.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>IMPACT Strategic Research Center, Deakin University, Geelong, Australia. dr.michaelmaes@hotmail.com.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, State University of Londrina, Londrina, Brazil. dr.michaelmaes@hotmail.com.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Revitalis, Waalre, the Netherlands. dr.michaelmaes@hotmail.com.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria. dr.michaelmaes@hotmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>02</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mol Neurobiol</MedlineTA>
<NlmUniqueID>8900963</NlmUniqueID>
<ISSNLinking>0893-7648</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cytokines</Keyword>
<Keyword MajorTopicYN="N">IDO</Keyword>
<Keyword MajorTopicYN="N">Immune</Keyword>
<Keyword MajorTopicYN="N">Inflammation</Keyword>
<Keyword MajorTopicYN="N">Kynurenine</Keyword>
<Keyword MajorTopicYN="N">Oxidative stress</Keyword>
<Keyword MajorTopicYN="N">Schizophrenia</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>09</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>01</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>2</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>2</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>2</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28181189</ArticleId>
<ArticleId IdType="doi">10.1007/s12035-017-0417-6</ArticleId>
<ArticleId IdType="pii">10.1007/s12035-017-0417-6</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Brésil</li>
<li>France</li>
<li>Norvège</li>
<li>Royaume-Uni</li>
<li>Thaïlande</li>
</country>
<region><li>Angleterre</li>
<li>Aquitaine</li>
<li>Aquitaine-Limousin-Poitou-Charentes</li>
<li>Ceará</li>
<li>Grand Londres</li>
</region>
<settlement><li>Bordeaux</li>
<li>Londres</li>
<li>Talence</li>
</settlement>
<orgName><li>Université fédérale du Ceará</li>
</orgName>
</list>
<tree><country name="Thaïlande"><noRegion><name sortKey="Kanchanatawan, Buranee" sort="Kanchanatawan, Buranee" uniqKey="Kanchanatawan B" first="Buranee" last="Kanchanatawan">Buranee Kanchanatawan</name>
</noRegion>
<name sortKey="Maes, Michael" sort="Maes, Michael" uniqKey="Maes M" first="Michael" last="Maes">Michael Maes</name>
<name sortKey="Ruxrungtham, Kiat" sort="Ruxrungtham, Kiat" uniqKey="Ruxrungtham K" first="Kiat" last="Ruxrungtham">Kiat Ruxrungtham</name>
<name sortKey="Sirivichayakul, Sunee" sort="Sirivichayakul, Sunee" uniqKey="Sirivichayakul S" first="Sunee" last="Sirivichayakul">Sunee Sirivichayakul</name>
</country>
<country name="Brésil"><region name="Ceará"><name sortKey="Carvalho, Andre F" sort="Carvalho, Andre F" uniqKey="Carvalho A" first="André F" last="Carvalho">André F. Carvalho</name>
</region>
</country>
<country name="France"><region name="Aquitaine-Limousin-Poitou-Charentes"><name sortKey="Geffard, Michel" sort="Geffard, Michel" uniqKey="Geffard M" first="Michel" last="Geffard">Michel Geffard</name>
</region>
</country>
<country name="Norvège"><noRegion><name sortKey="Ormstad, Heidi" sort="Ormstad, Heidi" uniqKey="Ormstad H" first="Heidi" last="Ormstad">Heidi Ormstad</name>
</noRegion>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Anderson, George" sort="Anderson, George" uniqKey="Anderson G" first="George" last="Anderson">George Anderson</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E72 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000E72 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:28181189 |texte= Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:28181189" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |